Coupling germline genetics to interferon-alpha responses in polycythemia vera treatment

Pegylated interferon alfa-2 (PEG-IFN) induces high response rates in many patients with polycythemia vera (PV),...

The role of inflammation in MPN and its therapeutic management

Myeloproliferative neoplasms (MPN) are a group of hematological malignancies characterized by aberrant clonal expansion of hematopoietic...

Use of ruxolitinib in patients with severe COVID-19

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor that has a good safety profile and is currently approved for the treatment of...

What is the news about ropeginterferon?

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR,...

Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms

The bone marrow niche is the local tissue microenvironment that maintains and regulates stem...

The role of inflammation in MPN and its therapeutic management

Myeloproliferative neoplasms (MPN) are a group of hematological malignancies characterized by aberrant clonal expansion of hematopoietic...

Use of ruxolitinib in patients with severe COVID-19

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor that has a good safety profile and is currently approved for the treatment of...

What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?

During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to Abdulraheem Yacoub, University...

The role of inflammation in MPN and its therapeutic management

Myeloproliferative neoplasms (MPN) are a group of hematological malignancies characterized by aberrant clonal expansion of hematopoietic...

Final phase II results of the SMAC mimetic LCL161 for intermediate/high-risk myelofibrosis

The efficacy and safety of the LCL161 was assessed in patients with relapsed or refractory MF of...

TET2 mutations predict thrombotic risk in patients with polycythemia vera

There is limited data on the role of DTA mutations in the prediction of thrombotic risk in patients with MPN. For...

Review of novel agents for myeloproliferative neoplasms

In the last 15 years, there have been rapid advances in understanding the importance and therapeutic potential of the Janus kinase/signal...